Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Am J Health Syst Pharm. 2013 Jan 15;70(2):113-25. doi: 10.2146/ajhp110601.

New oral therapies for the prevention and treatment of venous thromboembolism.

Author information

  • 1Department of Pharmacy Practice, College of Pharmacy, South Dakota State University, Sioux Falls, SD, USA.

Abstract

PURPOSE:

Data comparing traditional and novel anticoagulants are reviewed, and the potential use of new oral agents for the prevention and treatment of venous thromboembolism (VTE) is assessed.

SUMMARY:

Practical challenges in using traditional anticoagulants are well established and have led to the search for new oral agents. Apixaban, rivaroxaban, and dabigatran etexilate are new oral anticoagulants that may offer simpler, more effective, and safer treatment and prevention of VTE, which may increase adherence to such therapy, improve outcomes, and decrease overall health care costs. Their immediate onset of anticoagulant effect, ease of oral administration, and lack of needed regular anticoagulation monitoring are of interest in the medical and pharmacy communities. However, in the treatment and prevention of VTE, more data will be needed to determine their ultimate place in therapy. This review is intended to provide pharmacists with an objective overview of practical considerations that can help them understand the clinical data to facilitate their selection of anticoagulants.

CONCLUSION:

Apixaban, rivaroxaban, and dabigatran etexilate are new oral agents for the prevention and treatment of VTE.

PMID:
23292264
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk